Stock listing
A2JRKN Stock Price, News, Filings & Events — Ascletis Pharma, Inc.
Selected listing: A2JRKN · LS · EUR · DE
This page tracks Ascletis Pharma, Inc.'s A2JRKN:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2JRKN:LS. A2JRKN:LS is the stock-level entry point for investors researching Ascletis Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2JRKN:LS
- Asset type
- Stock
- Market cap
- $1.38B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Ascletis Pharma, Inc. A2JRKN:LS stock context
This page tracks Ascletis Pharma, Inc.'s A2JRKN:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2JRKN:LS. A2JRKN:LS is the stock-level entry point for investors researching Ascletis Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Ascletis Pharma, Inc.
Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong St...
September 7, 2026
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonis...
August 30, 2026
Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Recept...
August 10, 2026
Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Cla...
August 3, 2026
Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight ...
July 27, 2026
Research Ascletis Pharma, Inc.
Ascletis Pharma, Inc. investor report
Review AI stock analysis and investor report context for A2JRKN:LS.
Ascletis Pharma, Inc. company profile
View the public company page for Ascletis Pharma, Inc. on 6ix.
Ascletis Pharma, Inc. news
Read company news and market updates connected to Ascletis Pharma, Inc..
Ascletis Pharma, Inc. investor events
Find investor webinars, events, and replay context for Ascletis Pharma, Inc..
Alternate listings
1672:HKEX
HK · HKD
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
2VJ:TRADEGATE
DE · EUR
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
ASCLF:OTC
US · USD
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
A2JRKN:LSX
DE · EUR
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
2VJ:GETTEX
DE · EUR
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
2VJ:FWB
DE · EUR
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
2VJ:DUS
DE · EUR
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
2VJ:MUN
DE · EUR
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.
2VJ:SWB
DE · EUR
Alternate listing for Ascletis Pharma, Inc.; the primary context on this page is A2JRKN:LS.